See the DrugPatentWatch profile for Vidaza
What is Vidaza?
Vidaza (azacitidine) is a hypomethylating agent approved by the FDA for the treatment of myelodysplastic syndromes (MDS) and low‑risk acute myeloid leukemia (AML). It works by incorporating into DNA and inhibiting DNA methyltransferase, which reactivates tumor‑suppression genes and induces cell differentiation and apoptosis. [1]
When is Vidaza prescribed?
Oncologists typically prescribe Vidaza for patients who have not achieved remission with standard chemotherapy, for those who are not candidates for intensive induction therapy, or for patients with transfusion‑dependent anemia from MDS. It is also used in first‑line therapy for low‑ to intermediate‑2 risk MDS. [2]
How does Vidaza compare to decitabine?
Both drugs are nucleoside analogues that inhibit DNA methylation, yet they differ in dosing schedules and side‑effect profiles. Vidaza is given as a subcutaneous injection 5 days a month for 4–6 months, while decitabine is administered intravenously for 5 days every 4 weeks. Clinical studies show comparable overall response rates, but Vidaza often has a lower incidence of myelosuppression. [3]
What are the main side effects?
Common adverse events include myelosuppression (neutropenia, thrombocytopenia), nausea, fatigue, and infusion‑site reactions. Rarely, patients may develop severe infections, gastrointestinal bleeding, or secondary malignancies. Close monitoring of blood counts and supportive care are essential. [4]
Can Vidaza be combined with other agents?
Vidaza is frequently paired with venetoclax, a BCL‑2 inhibitor, for AML patients who are unfit for intensive chemotherapy. The combination has shown higher remission rates but also increased neutropenia. Other combinations under investigation involve hypomethylating agents with checkpoint inhibitors or targeted therapies. [5]
What is the dosing schedule for Vidaza?
Typical dosing is 75 mg/m² administered subcutaneously on days 1–5 of a 28‑day cycle, repeated for 4–6 cycles. Adjustments are made for renal impairment, low blood counts, or infusion reactions.
Is Vidaza still under patent protection?
The original patent for azacitidine (Vidaza) was granted in the 1980s, and subsequent patents covering specific formulations and dosing regimens expired between 2014 and 2020. Currently, Vidaza remains under brand protection, but several generic versions are available in the United States and Europe. PatentWatch lists the current patent status and pending litigations. [6]
What are the latest research developments?
Ongoing trials explore Vidaza’s use in myeloproliferative neoplasms, as maintenance therapy after stem‑cell transplant, and in combination with novel epigenetic modulators. Early data suggest potential benefits in prolonging disease‑free survival.
How does Vidaza fit into treatment guidelines?
The National Comprehensive Cancer Network (NCCN) recommends Vidaza for low‑ and intermediate‑risk MDS and as a first‑line option for AML in patients who cannot tolerate intensive induction. It is also considered in salvage settings when other therapies fail.
Do patients need to be concerned about drug interactions?
Vidaza has limited drug‑drug interactions, but concurrent use of agents that cause cytopenias (e.g., other myelosuppressive chemotherapy) or certain antivirals may increase toxicity. Patients should disclose all medications, including supplements, to avoid adverse interactions.
What does the cost of Vidaza look like?
The average wholesale price for Vidaza is around $1,800 per 75‑mg vial, but insurance coverage and patient assistance programs can lower out‑of‑pocket expenses. Generic versions are priced significantly lower.
What should patients watch for after starting therapy?
Patients should report fever, sore throat, bruising, or bleeding promptly, as these may signal severe neutropenia or thrombocytopenia. Regular blood tests every 1–2 weeks during the first few cycles are standard.
Where can I find more detailed patent information?
DrugPatentWatch provides up‑to‑date details on Vidaza’s patent landscape, including expiration dates, litigations, and market exclusivity data.
---
Sources
1. FDA prescribing information for Vidaza (azacitidine)
2. NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes
3. Comparative study of azacitidine vs. decitabine in MDS (JAMA Oncology)
4. Common adverse events report, FDA Adverse Event Reporting System
5. Clinical trial NCT02501418 (Vidaza + venetoclax in AML)
6. DrugPatentWatch.com – Azacitidine patents and status (link)